Characteristics of [18F]FET PET and MRI in isocitrate dehydrogenase (IDH)-mutant gliomas diagnosed according to the WHO 2021 classification - a retrospective analysis.

doi:10.1007/s00259-026-07760-2

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Characteristics of [18F]FET PET and MRI in isocitrate dehydrogenase (IDH)-mutant gliomas diagnosed according to the WHO 2021 classification - a retrospective analysis.

European journal of nuclear medicine and molecular imaging - 1 May 2026

Barci Enio, Mair Maximilian J, Reis Jonas, Müller Katharina, Isakaj Jera, Istrefi Ergi, von Polenz Isabelle, Siegmund Sophie C, Kaiser Lena, Preusser Matthias, Schichor Christian, Thon Niklas, Harter Patrick, von Baumgarten Louisa, Forbrig Robert, Albert Nathalie L

Abstract excerpt

PURPOSE: Amino acid positron emission tomography (PET) is increasingly utilized in the clinical workup of patients with glioma. To better understand the PET characteristics of IDH-mutant glioma according to the 2021 WHO classification of CNS tumours, this retrospective study explored the association between amino acid PET and magnetic resonance imaging (MRI) characteristics in patients with newly diagnosed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Positron-Emission Tomography

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Brain Neoplasms

Share to Glioma

Share to Isocitrate Dehydrogenase

Share to Magnetic Resonance Imaging

Share to Positron Emission Tomography Computed Tomography

Share to Tyrosine

Share to World Health Organization

Source

Open in PubMed Open full text

Identifiers

PMID: 41571842
DOI: 10.1007/s00259-026-07760-2
PMCID: PMC13121362

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characteristics of [18F]FET PET and MRI in isocitrate dehydrogenase (IDH)-mutant gliomas diagnosed according to the WHO 2021 classification - a retrospective analysis.PMID 41571842Read ↗

Pre-operative dual-time-point [18F]FET PET differentiates CDKN2A/B loss and PIK3CA mutation status in adult-type diffuse glioma: a single-center prospective study.Semantic proximity Read ↗

Spatial tumour characteristics as an indirect marker of metabolic dysregulation: evaluation for non-invasive IDH-genotyping of glioma using hybrid [18 F]FET-PET/MRI.Semantic proximity Read ↗

Distinguishing IDH-mutant astrocytomas from IDH-wildtype glioblastomas using qualitative and quantitative MRI features: a WHO CNS5 study.Semantic proximity Read ↗

Clinical features, MRI, molecular alternations, and prognosis of astrocytoma based on WHO 2021 classification of central nervous system tumors: A single-center retrospective study.Semantic proximity Read ↗

Prognostic stratification of newly diagnosed IDH-mutant gliomas by [18F]fluoroethyltyrosine and [11C]methionine PET: A retrospective, bicentric cohort study.Semantic proximity Read ↗

Unveiling intratumoral heterogeneity and isocitrate dehydrogenase status in gliomas: a simultaneous fluorine-18 fluorodeoxyglucose PET/MRI study based on 2021 WHO classification.Semantic proximity Read ↗

Predictive IDH Genotyping Based on the Evaluation of Spatial Metabolic Heterogeneity by Compartmental Uptake Characteristics in Preoperative Glioma Using 18F-FET PET.Semantic proximity Read ↗

A comprehensive clinical, molecular, radiological, and surgical analysis for predicting prognosis in isocitrate dehydrogenase-mutant astrocytoma patients.Semantic proximity Read ↗

Fluid attenuation in non-contrast-enhancing tumor (nCET): an MRI Marker for Isocitrate Dehydrogenase (IDH) mutation in Glioblastoma.Semantic proximity Read ↗

The Value of FET PET/CT in Recurrent Glioma with a Different IDH Mutation Status: The Relationship between Imaging and Molecular Biomarkers.Semantic proximity Read ↗

Clinical applications and prospects of PET imaging in patients with IDH-mutant gliomas.Semantic proximity Read ↗

SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.